White & Case Advises Takeda on Agreement to Divest Select OTC and Non-Core Assets to Acino for Over US$200 Million

Press Release
1 min read

Global law firm White & Case LLP has advised Takeda on the agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa (NEMEA) countries within its Growth and Emerging Markets Business Unit to Acino for a total value in excess of US$200 million.

Takeda Pharmaceutical Company Limited is a global biopharmaceutical leader headquartered in Japan, primarily focused on five business areas: Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience.

Acino is a Swiss pharmaceutical company headquartered in Zurich, with a clear focus on selected markets in the Middle East, Africa, the CIS Region, and Latin America.

The White & Case team which advised on the transaction was led by partners Michael Immordino and Leonardo Graffi (both Milan and London) and included partners Philip Trillmich, Monica Holden, Dominic Ross and Nicholas Greenacre (all London), James Hayden (New York) and Axel Schulz (Brussels), counsels Isaac Tendler (New York) and Ajita Shukla (Washington DC), and associates Andrea Pretti and Fabrizia Faggiano (both Milan), Chris Ewing and Kate Russell (both London), Kyle Oh (Singapore), Tommaso Poli (Brussels) and lawyer Mariasole Maschio (Milan).

Press contact
For more information please speak to your local media contact.